Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q1 2024 (March 31)6holders
$10.75avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings. The largest holders were Hantz Financial Services, Inc. ($1.4M), Rhumbline Advisers ($408K) and GAMMA Investing LLC ($26K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $8K |
Ownership 6 holders
| Hantz Financial Services, Inc. | 0.03% | Add +14.3% | 128,702 | $1.4M |
| Rhumbline Advisers | 0.00% | Add +10.1% | 37,924 | $408K |
| GAMMA Investing LLC | 0.01% | Add +863.9% | 2,400 | $26K |
| PNC Financial Services Group, Inc. | 0.00% | Add +21.3% | 307 | $3K |
| Operose Advisors LLC | 0.00% | No change | 90 | $968 |
| First Horizon Advisors, Inc. | 0.00% | Reduce -67.5% | 37 | $397 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.